Tecan Group AG (SWX:TECN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 1.60B -39.3% |
| Revenue (ttm) | 906.60M -9.3% |
| Net Income | 63.13M -37.7% |
| EPS | 4.95 -37.2% |
| Shares Out | 12.70M |
| PE Ratio | 25.39 |
| Forward PE | 19.75 |
| Dividend | 3.00 (2.34%) |
| Ex-Dividend Date | Apr 14, 2025 |
| Volume | 61,317 |
| Average Volume | 47,758 |
| Open | 125.80 |
| Previous Close | 125.70 |
| Day's Range | 121.70 - 128.50 |
| 52-Week Range | 120.50 - 191.70 |
| Beta | 1.25 |
| RSI | 43.14 |
| Earnings Date | Mar 16, 2026 |
About Tecan Group AG
Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments, Life Sciences Business and Partnering Business. The company offers liquid handling and automation, microplate readers and washers, software, consumables, NGS reagents, immunoassays and antibodies, and Tecan Labwerx, an end-to-end automation solution. It also provides PARAMIT, a contract design and manufacturing service; Synergence, a customized O... [Read more]
Financial Performance
In 2024, Tecan Group AG's revenue was 934.28 million, a decrease of -13.04% compared to the previous year's 1.07 billion. Earnings were 67.66 million, a decrease of -48.77%.
Financial StatementsNews
Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confirms full-year 2025 outlook
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confir...